Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Oct 25, 2021

SELL
$7.78 - $10.0 $233,259 - $299,820
-29,982 Closed
0 $0
Q2 2021

Jul 23, 2021

BUY
$9.22 - $14.48 $276,434 - $434,139
29,982 New
29,982 $279,000

Others Institutions Holding NUVB

About Nuvation Bio Inc.


  • Ticker NUVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 217,244,000
  • Market Cap $480M
  • Description
  • Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...
More about NUVB
Track This Portfolio

Track Exos Asset Management LLC Portfolio

Follow Exos Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exos Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Exos Asset Management LLC with notifications on news.